Uniunea Europeană - română - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrita, reumatoida - imunosupresoare - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gilead sciences ireland uc - irlanda - amphotericinum b - pulb. pt. conc. pt. dispersie perf. - antimicotice de uz sistemic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gilead sciences ireland uc - irlanda - filgotinibum - compr. film. - 100mg - imunosupresoare imunosupresoare selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gilead sciences ireland uc - irlanda - filgotinibum - compr. film. - 200mg - imunosupresoare imunosupresoare selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lyocontract gmbh - germania - bulevirtidum - pulb. pt. sol. inj. - 2mg - antivirale cu actiune directa alte antivirale

Uniunea Europeană - română - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agenți antineoplazici - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle-cell - agenți antineoplazici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).